The Clinical, Epidemiological and Treatment Characteristics of Head and Neck Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Pecs
About this trial
The aim of our study is to prospectively collect information regarding (1) the demographic, lifestyle-related and clinical characteristics of patients with head and neck cancer and (2) the waiting times to diagnosis and therapy, and the 1-, 3- and 5-year survival of patients. We plan to gain insight into the characteristics and pathways of head and neck cancer patients in Baranya County, which can in turn help to identify factors that lead to improved or worse disease outcomes. (Thus, these factors can subsequently eliminated or lessened to improve the outcome of head and neck cancer patients. )
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients 18 years or over presenting with head and neck cancer (with morphology of squamocellular carcinoma), who are subsequently given one of the following ICD-10 codes: Malignant neoplasms of lip, oral cavity and pharynx (C00-C14), Malignant neoplasm of larynx (C32) and for whom this is their first cancer.
Disqualifiers
Patients who do not meet the inclusion criteria and patients who meet the inclusion criteria but for whom this is a second or recurrent cancer (they already have an "ICD-C" code) are excluded from the study
Trial population
Patients 18 years or over with primary head-neck cancer (with morphology of squamocellular carcinoma, ICD codes: C00-C14, C32) and no previously documented cancer.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionNo intervention.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Characterization of patient pathways
Initial symptoms, waiting times to diagnosis and treatment, type of healthcare provision
Time frame
2021-20242
Lifestyle-related factors
The effects of demographic and lifestyle-related factors on clinical outcome(s) using follow-up data
Time frame
2021-20263
Hard endpoint outcomes: Overall survival, time to metastasis, disease-free survival
Assessment of overall survival, time to metastasis, disease-free survival
Time frame
2021-2029Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov